Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?

Area of Science:

• Biochemistry
• Cardiovascular Science
• Enzymology

Background:

• Lecithin cholesterol acyl transferase (LCAT) esterifies cholesterol and elevates HDL cholesterol.
• LCAT's precise role in atherosclerosis remains unclear, with conflicting animal study results.
• Studies in rabbits and non-human primates suggest LCAT is atheroprotective.

Purpose of the Study:

• To investigate the role of LCAT in atherosclerosis.
• To explore the potential of LCAT as a therapeutic target for cardiovascular disease.

Main Methods:

• Review of animal model studies (rabbits, non-human primates).
• Analysis of existing biomarker and patient imaging studies.
• Consideration of recombinant LCAT development for therapeutic applications.

Main Results:

• Animal models, especially primates, suggest LCAT has atheroprotective effects.
• Lack of definitive biomarker studies linking LCAT mechanistically to cardiovascular disease.
• Imaging studies in LCAT-deficient patients have not clarified LCAT's role in atherosclerosis.

Conclusions:

• LCAT is likely atheroprotective, particularly in species mimicking human lipoprotein metabolism.
• Further research is required to establish a clear mechanistic link between LCAT and cardiovascular disease.
• Recombinant LCAT shows promise for treating genetic LCAT disorders, renal disease, and potentially acute coronary syndrome.